Clinical Trial Search

Phase 3 N=2,044 A Clinical Study to Evaluate the Immunogenicity and Safety of an Adjuvanted Quadrivalent Influenza Vaccine Compared With a Licensed Quadrivalent Vaccine in Adults 50 to 64 Years of Age

Influenza, Human

Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio of Hemagglutination Inhibition (HI) Antibodies at Day 22 for the A/H1N1, A/H3N2, B/Yamagata, and…

Seqirus Results Sep 2023 3.0% serious AE View details

Phase 3 N=548 CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Ulcerative Colitis (LIBERTY-UC)

Ulcerative Colitis

Primary: Percentage of Patients Achieving Clinical Remission at Week 54 — 127; 30 Participants — p=<0.0001

Celltrion Results Sep 2023 4.3% serious AE View details

Phase 3 N=560 Clinical Study Comparing Two Models of a Travoprost Intraocular Implant

Glaucoma, Open-Angle · Ocular Hypertension

Primary: Change From Baseline in Diurnal IOP (as Measured at 8AM and 10AM) Through 3 Months Postoperative — -8.26; -8.40; -7.16; -8.20 mmHg

Glaukos Corporation Results Sep 2023 2.1% serious AE View details

Phase 3 N=375 An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

Dravet Syndrome

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period — 98.1 percentage of participants

Zogenix International Limited, Inc., a… Results Sep 2023 26.5% serious AE View details

Phase 3 N=376 Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)

Chronic Cough

Primary: Percent Change From Baseline in Average Daily Cough-induced Stress Urinary Incontinence (SUI) Episodes at Week 12 — -41.09; -52.78 Percent Change — p=0.004

Merck Sharp & Dohme LLC Results Sep 2023 1.3% serious AE View details

Phase 3 N=176 Phase 3 Study to Evaluate the Safety and Efficacy of Galnobax® in Treating Diabetic Foot Ulcers

Diabetic Foot Ulcer

Primary: Proportion of Subjects Achieving Target Ulcer Closure Within 12-week Treatment Phase, as Assessed by Blinded Investigator — 41; 30; 10 Participants — p=0.0276

Novalead Pharma Private Limited Results Sep 2023 4.0% serious AE View details

Phase 3 N=131 Contrast-enhanced Ultrasound Evaluation of Chemoembolization

Hepatocellular Carcinoma · Chemoembolization, Therapeutic

Primary: Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization — 94 percentage

Sidney Kimmel Comprehensive Cancer Center at… Results Sep 2023 3.9% serious AE View details

Phase 3 N=15 Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity

Pro-opiomelanocortin (POMC) Deficiency Obesity

Primary: Percentage of Participants Who Reached ≥10% Weight Loss Threshold After 1 Year (Pivotal Cohort) — 80.0 percentage of participants — p=<0.0001

Rhythm Pharmaceuticals, Inc. Results Sep 2023 40.0% serious AE View details

Phase 3 N=192 Clinical Investigation Using MED3000 Gel or Tadalafil Tablets in the Treatment of Erectile Dysfunction

Erectile Dysfunction

Primary: Change From Baseline in the Erectile Function (EF) Domain of the International Index of Erectile Function (IIEF) Questionnaire, in Patients Randomised to MED3000, at…

Futura Medical Developments Ltd. Results Sep 2023 0.5% serious AE View details

Phase 3 N=152 A Study Assessing the Safety and Effectiveness of IC2000 and SPY Fluorescence Imaging Systems (SPY-PHI) in the Visualization of Lymphatic Vessels and Identification of Lymph Nodes During Sentinel Lymph Node Biopsy in Subjects With Breast Cancer

Breast Cancer · Lymph Node Mapping · Sentinel Lymph Node Biopsy

Primary: Proportion of Lymph Nodes Identified by IC2000/SPY-PHI Compared to the Proportion of Lymph Nodes Identified by Tc99m/Gamma Probe — 360; 266 Lymph Nodes — p=<0.0001

Novadaq Technologies ULC, now a part of Stryker Results Sep 2023 2.7% serious AE View details

Phase 3 N=126 A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

Prader-Willi Syndrome

Primary: Hyperphagia Questionnaire (HQ-CT) Change From Baseline at Visit 7 (Week 13) — -5.94; -4.27 score on a scale — p=0.1983

Soleno Therapeutics, Inc. Results Sep 2023 4.8% serious AE View details

Phase 3 N=925 A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Respiratory Syncytial Virus Infections

Primary: Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)…

AstraZeneca Results Sep 2023 12.5% serious AE View details

Phase 3 N=315 Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

Episodic Migraine

Primary: Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population — -1.86; -4.29 migraine days per month — p=<0.0001

Allergan Results Sep 2023 1.3% serious AE View details

Phase 3 N=591 A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes

Diabetes Mellitus · Diabetes Mellitus, Type 2 · Glucose Metabolism Disorders

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 — -1.53; -1.25 Percentage of HbA1c — p=<.001

Eli Lilly and Company Results Sep 2023 3.8% serious AE View details

Phase 3 N=345 A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type

Agitation Associated With Alzheimer's Dementia · Alzheimer Dementia

Primary: Change From Baseline to Week 12 in the CMAI Total Score — -22.6; -17.3 score on a scale — p=0.0026

Otsuka Pharmaceutical Development &… Results Sep 2023 2.6% serious AE View details